Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer—A Study of the GANNET53 Consortium

Background: Stabilized mutant p53 protein (mutp53) is a novel target in epithelial ovarian cancer. Due to aberrant conformation, mutp53 proteins depend on folding support by the Hsp90 chaperone. Hsp90 blockade induces degradation of mutp53, resulting in tumor cell cytotoxicity and increased sensitiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Ray-Coquard, Isabelle, Braicu, Ioana, Berger, Regina, Mahner, Sven, Sehouli, Jalid, Pujade-Lauraine, Eric, Cassier, Philippe Alexandre, Moll, Ute Martha, Ulmer, Hanno, Leunen, Karin, Zeimet, Alain Gustave, Marth, Christian, Vergote, Ignace, Concin, Nicole
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6746955/
https://www.ncbi.nlm.nih.gov/pubmed/31552170
http://dx.doi.org/10.3389/fonc.2019.00832

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6746955/
https://www.ncbi.nlm.nih.gov/pubmed/31552170
http://dx.doi.org/10.3389/fonc.2019.00832

Ejemplares similares